Is radiomic MRI a feasible alternative to OncotypeDX® recurrence score testing? A systematic review and meta-analysis.
Matthew G DaveyM S DaveyÉ J RyanMichael R BolandP F McAnenaA J LoweryM J KerinPublished in: BJS open (2021)
Radiomic tumour analysis is comparable to RS in differentiating patients into clinically relevant subgroups. For patients requiring MRI, radiomics may complement and enhance RS for prognostication and therapeutic decision making in ER+ breast cancer.